EverSource Wealth Advisors’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.17K Sell
77
-100
-56% -$9.41K ﹤0.01% 3101
2026
Q1
$15.7K Buy
177
+142
+406% +$14.6K ﹤0.01% 2651
2025
Q4
$3.33K Sell
35
-27
-44% -$2.72K ﹤0.01% 3295
2025
Q3
$6.12K Buy
62
+5
+9% +$535 ﹤0.01% 3069
2025
Q2
$6.07K Sell
57
-55
-49% -$5.55K ﹤0.01% 3068
2025
Q1
$10.2K Buy
112
+2
+2% +$224 ﹤0.01% 2100
2024
Q4
$12.5K Hold
110
– – ﹤0.01% 1881
2024
Q3
$13.1K Sell
110
-373
-77% -$34.3K ﹤0.01% 1720
2024
Q2
$41.6K Sell
483
-6
-1% -$548 ﹤0.01% 1173
2024
Q1
$43.4K Buy
489
+252
+106% +$24.2K ﹤0.01% 1034
2023
Q4
$25K Sell
237
-618
-72% -$62.3K ﹤0.01% 1144
2023
Q3
$92.9K Buy
855
+556
+186% +$61.5K 0.01% 590
2023
Q2
$32.3K Buy
299
+114
+62% +$12.8K ﹤0.01% 991
2023
Q1
$23K Sell
185
-203
-52% -$27.9K ﹤0.01% 1027
2022
Q4
$58.3K Buy
+388
New +$59.7K 0.01% 705
2022
Q3
– Sell
-360
Closed -$54K – 1979
2022
Q2
$54K Buy
+360
New +$55K 0.01% 603

Other funds holding BNTX

EverSource Wealth Advisors's BNTX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its BioNTech (BNTX) stake by 56% in Q2 2026, selling an estimated $9.41K and leaving 77 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3101.

EverSource Wealth Advisors first reported a position in BNTX in Q2 2022 and has held it in 16 quarters since. The position peaked at $92.9K in Q3 2023. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

  • EverSource Wealth Advisors held 77 shares of BioNTech worth $7.17K as of Q2 2026.
  • EverSource Wealth Advisors sold 100 BioNTech shares in Q2 2026, an estimated $9.41K.
  • BioNTech made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3101 holding.
  • EverSource Wealth Advisors first reported a position in BioNTech in Q2 2022 and has held it in 16 quarters since.
  • EverSource Wealth Advisors's BioNTech position peaked at $92.9K in Q3 2023.
  • 282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.